Navigation Links
Cell Biosciences Closes $10 Million Series C Financing
Date:4/9/2009

PALO ALTO, Calif., April 9 /PRNewswire/ -- Cell Biosciences, a provider of nanoproteomic analysis systems to life science researchers, today announced the closing of a $10 million Series C financing led by its largest shareholder, the Wellcome Trust. Existing investors Domain Associates, Latterell Venture Partners, Novo A/S, Mitsui Ventures, Royal Bank of Canada and The Vertical Group also participated in the financing.

"We are very happy to announce this financing in the current economic environment and we believe it represents a strong vote of confidence by our investors in the potential of the technology and team at Cell Biosciences," said Tim Harkness, President and Chief Executive Officer of Cell Biosciences. "This investment should allow us to fully execute our plan to bring this revolutionary proteomics technology to the broad life sciences market."

The Cell Biosciences platform is an ultrasensitive nanofluidic immunoassay system designed to analyze proteins in extremely small biological samples. Researchers use our products to discover subtle details about phosphoprotein signaling in a wide variety of biological systems. Cell Biosciences has sold systems and established direct distribution organizations in North America and Europe. This month the company will launch its next generation protein analysis system, the CB1000, at the American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado.

"We continue to believe that the Cell Biosciences platform is an important enabling technology for biomarker discovery and ultimately can make a real difference in patient care," added Julie Eskay-Eagle, Cell Biosciences board member and the Head of Health Care Investments for the Wellcome Trust.

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems, software, and assay pro
'/>"/>

SOURCE Cell Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... N.J. , April 30, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... results for the first quarter of 2015 on May ... Roka Bioscience will also host a conference ... 2015 to discuss its first quarter financial results. During ...
(Date:4/30/2015)... 2015 Nitto Avecia, a leading ... increased capacity and production capability to serve biotechnology ... and service fulfillment continues to drive Nitto Avecia ... throughput capacities. , In Fall 2014, ... process equipment at its Milford, MA facility, which ...
(Date:4/30/2015)...  The Paul G. Allen Family Foundation announced today ... six groups of researchers with projects at the frontier ... growing mature human brain cells in the laboratory. The ... over three years.  "This new cohort ... significant because the field of neuronal maturation is at ...
(Date:4/30/2015)... April 30, 2015 WuXi PharmaTech (Cayman) Inc. ... leading global contract R&D services provider, today announced that ... proposal letter, dated April 29, 2015, from a consortium ... (the "Chairman"), founder, chairman and chief executive officer of ... that proposes a transaction (the "Transaction") involving the acquisition ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... Annual Observance To Draw Attention To ,The Sneak Thief ... an effort to combat one of the,main causes of ... World Glaucoma Patient Organization have announced the first annual,World ... The day will be marked,by awareness and educational events ...
... and CLAREMONT, Calif., Jan. 30 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech ... the volume of bio-enhanced feed products sold during ... quarter of 2007 and increased,25% over the same ... Feed Co., Ltd. ("Kiwa Tianjin") is a joint-venture ...
... Tengion Inc., a clinical,stage regenerative medicine company focused ... that Steven Nichtberger, M.D.,President and Chief Executive Officer, ... Biotechnology and Medical Device Conference on,Tuesday, February 5, ... be held at,the Grand Hyatt Hotel in New ...
Cached Biology Technology:World Glaucoma Day Set for March 6th 2Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007 2
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/9/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the third quarter ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-438-5524 ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... risks posed by pharmaceuticals are not enough to protect ... of Gothenburg (Sweden) who is calling for better environmental ... the combined effects of different drugs to reflect the ... Brosch from the Department of Plant and Environmental Sciences ...
... of scientists from Singapore led by the Genome Institute ... Cell Biology (IMCB), two biomedical research institutes of ... discovered the most important genes in human embryonic stem ... stem cells work. Their research, published in top scientific ...
... National Laboratory researcher Bette Korber is part of an ... the first human trial of a mosaic HIV vaccine ... the virus that causes AIDS by attempting to address ... design: the virus,s extensive genetic diversity. The team ...
Cached Biology News:Environmental risk assessment of pharmaceuticals inadequate 2Singapore scientists first to perform genome-wide study of human stem cells 2Consortium to design human trials of mosaic HIV vaccine 2
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
Anti-HumanLactoferrin...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Biology Products: